The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Fangyuan, Zwinderman, Martijn R. H., Dekker, Frank J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017514/
https://www.ncbi.nlm.nih.gov/pubmed/29498635
http://dx.doi.org/10.3390/molecules23030551
_version_ 1783334767299657728
author Cao, Fangyuan
Zwinderman, Martijn R. H.
Dekker, Frank J.
author_facet Cao, Fangyuan
Zwinderman, Martijn R. H.
Dekker, Frank J.
author_sort Cao, Fangyuan
collection PubMed
description Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.
format Online
Article
Text
id pubmed-6017514
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60175142018-11-13 The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors Cao, Fangyuan Zwinderman, Martijn R. H. Dekker, Frank J. Molecules Review Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future. MDPI 2018-03-02 /pmc/articles/PMC6017514/ /pubmed/29498635 http://dx.doi.org/10.3390/molecules23030551 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cao, Fangyuan
Zwinderman, Martijn R. H.
Dekker, Frank J.
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
title The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
title_full The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
title_fullStr The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
title_full_unstemmed The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
title_short The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
title_sort process and strategy for developing selective histone deacetylase 3 inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017514/
https://www.ncbi.nlm.nih.gov/pubmed/29498635
http://dx.doi.org/10.3390/molecules23030551
work_keys_str_mv AT caofangyuan theprocessandstrategyfordevelopingselectivehistonedeacetylase3inhibitors
AT zwindermanmartijnrh theprocessandstrategyfordevelopingselectivehistonedeacetylase3inhibitors
AT dekkerfrankj theprocessandstrategyfordevelopingselectivehistonedeacetylase3inhibitors
AT caofangyuan processandstrategyfordevelopingselectivehistonedeacetylase3inhibitors
AT zwindermanmartijnrh processandstrategyfordevelopingselectivehistonedeacetylase3inhibitors
AT dekkerfrankj processandstrategyfordevelopingselectivehistonedeacetylase3inhibitors

Ejemplares similares